We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 2.34% | 219.00 | 218.00 | 219.00 | 224.50 | 214.00 | 214.00 | 837,599 | 16:29:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 23.75M | -50.35M | -0.1839 | -11.91 | 599.77M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/1/2024 16:53 | These UT trades at the end of each day are relentless :-( | return_of_the_apeman | |
11/1/2024 13:47 | feels like we are walked down by market makers. seems odd given our new found very strong balance sheet. i have added on the dip.. | edwardt | |
11/1/2024 10:20 | Plenty of smaller holders clearly wanted more immediate returns and are exiting - nice to hear the longer term plan seems to be on track :) | takeiteasy | |
11/1/2024 08:33 | At JPM CEO called 100pc owned Seaport 'Karuna on steroids'.set up by the original Karuna team.I would expect pre IPO money from the institutions who have made billions from Karuna.Seaport certainly has the potential to become a $14bn company in coming years.this time around Puretech will be in position to have a much bigger slice of a very big pie. | colinblackbourn | |
11/1/2024 05:35 | Just looking at the chart 200 does seem more of a support than a resistance point, 250 may be more of a resistance point. This share has caused a lot of pain for holders over many years so there is not much love around at all yet and some looking for early exits - if this a much better year for biotech in general we may get an improved performance from the underlying businesses and more confidence from the market in this share - won't happen overnight I guess... | takeiteasy | |
10/1/2024 22:57 | Doctor 69. We did. Then we dropped. We might go back up again tomorrow. | daijavu | |
10/1/2024 21:31 | Vor up 22% - looks like there might be value there... | edwardt | |
10/1/2024 10:22 | We usually go up in the afternoon as usa opens | doctor 69 | |
10/1/2024 09:25 | At which point we will know their new "capital returns strategy" Watching the chart back test of £2 | return_of_the_apeman | |
10/1/2024 08:32 | According to the presentation the Karuna stake will be held until the deal closes in a couple of months which gives the full $330 per share.$294m.they already have $320m | colinblackbourn | |
10/1/2024 07:53 | Presenting this afternoon in the US. Hopefully we will get some more information on how it went over the next couple of days. | wildchild | |
10/1/2024 07:50 | Agree steady controlled rise . Well if 2023 was awful year for biotechs , once market turns it will be quality stocks like pure that will shine . The poor market of 2023 has given us a chance to pick up pure stock on the cheap . Upside looks very large and if market moves positively as interest rates get cut , then pure will deliver us big returns . | doctor 69 | |
10/1/2024 07:41 | There is a very interesting narrative in the BBH trust monthly update today about why 2023 went so horribly wrong for even the best biotechs - nothing we don't know of course but a useful reminder of the impact of certain key issues on investor sentiment. This stock feels like it is being very tightly controlled, tiny move by tiny move to avoid any jumps for short term traders to join the party. Just my hunch but we seem to be heading in the right direction at the moment little by little...dyor etc | takeiteasy | |
10/1/2024 03:27 | It has just followed the XBI, down down down no matter what the quality of the company. Does leave an awful lot of upside though, when sentiment towards the sector turns more favourable. | rambutan2 | |
09/1/2024 19:39 | ok, got you. Presentation is excellent with an interesting mental health treatment under development.. you only have to wonder where this has gone so wrong with such a sensible strategy and strong management. | takeiteasy | |
09/1/2024 19:01 | Actually since January 2021 takeiteasy when puretech hit 420 | brianblu | |
09/1/2024 17:26 | I wonder if the large trade done later this afternoon has been holding us back - perhaps we will find out tomorrow - would be good if we can break out of the consistent down channel chart trend (above) from early 2023... | takeiteasy | |
09/1/2024 12:44 | https://puretechheal | colinblackbourn | |
09/1/2024 12:27 | When you look at the 7 year chart puretech is still well below the median considering the latest developments,it was just so undervalued under £2 | linton5 | |
08/1/2024 20:42 | Peel hunt are smoking the good stuff. Let's get to £2.50 first | edwardt | |
08/1/2024 19:35 | Puretech Already stated y/e net cash will be $320m.892000 Karuna left.$282m value now or $294m on closing.$400m milestones to come.plus maybe another.$200m..$320m | colinblackbourn | |
08/1/2024 17:14 | PureTech Health plcPureTech to Present at 42(nd) Annual J.P. Morgan Healthcare ConferencePureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42(nd) Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST. A webcast of the presentation will be available at https://investors.pu | colinblackbourn | |
08/1/2024 17:12 | The 42nd Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA.This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. | colinblackbourn | |
08/1/2024 17:08 | Its a medical conference, surely more likely to hear about updates regarding the drugs pipeline! Details regarding cash return policy should simply be via an RNS at an appropriate time i.e when the deal completes or goes unconditional | rimau1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions